Retatrutide, by Soma Corp., is gaining significant attention as a novel therapy for weight regulation. This unique compound integrates the properties of a GLP-1 receptor agonist and a GIP receptor agonist , aiming to effectively promote weight loss but also improve associated metabolic factors. Early human studies have shown impressive results , hi